Business World: Acadia Pharm, ACP-103, & Parkinson Disease
Acadia Pharma Says Drug Study Encouraging
Wednesday June 22, 7:44 pm ET
Acadia Pharmaceuticals Says Lead Drug Helped Psychosis in Parkinson's Patients; Shares Fall
SAN DIEGO (AP) -- Acadia Pharmaceuticals Inc. on Wednesday said an ongoing mid-stage trial showed that its experimental drug did a better job than a placebo in reducing hallucinations and delusions in Parkinson's disease patients who suffer treatment-induced psychosis.
Acadia said patients taking ACP-103 -- its lead drug candidate -- showed a greater reduction in psychotic symptoms than those taking a placebo, particularly lower hallucinations and delusions. The study involves 60 patients and the interim data came from an analysis of the first 30 patients to complete the trial. Acadia said no serious side effects were reported from ACP-103.
[ ... Read the full article ... ]
" ACP-103, a proprietary small molecule discovered by ACADIA, is in development for treatment of the psychiatric and motoric dysfunction that frequently results from current Parkinson's disease therapies. ACP-103 is given orally and blocks the activity of the 5-HT2A receptor, a drug target that plays an important role in the treatment of various neuropsychiatric disorders."-
Anthony H. Risser | neuroscience | neuropsychology | brain